[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622352":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":24,"locations":30,"responsibleParty":41,"collaborators":10,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":10,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":10,"maxAge":10,"enrollmentInfo":53,"targetDuration":56,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":68,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Asan Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"endometrial cancer cohort",null,"patients diagnosed with endometrial cancer",[13],"Genetic: Serial blood collection for MRD testing",{"label":15,"type":10,"description":16,"interventionNames":17},"cervical cancer cohort","patients diagnosed with cervical cancer",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"GENETIC","Serial blood collection for MRD testing","Participants will undergo serial peripheral blood collection (approximately 20 mL per visit) at predefined clinical milestones: baseline (diagnosis), post-operative (2-4 weeks after surgery), post-adjuvant therapy (2-4 weeks after completion of chemotherapy or CCRT), and during follow-up surveillance (every 3 months for up to 24 months).\n\nThe collected blood will be used to perform Minimal Residual Disease (MRD) testing by analyzing circulating tumor DNA (ctDNA).\n\nArchival tumor tissue (FFPE blocks or slides) from initial diagnosis or surgery will also be collected to identify patient-specific somatic mutations for the MRD assay.\n\nThis study is observational and does not involve any changes to the patient's standard of care or medical treatment.",[15,9],[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Jeong-Yeol Park, M.D., Ph.D.","CONTACT","+82-2-3010-3630","jypark@amc.seoul.kr",[31],{"facility":5,"status":10,"city":32,"state":32,"zip":33,"country":34,"countryCode":10,"cosmosGeoPoint":35,"geoPoint":40,"contacts":10},"Seoul","05505","South Korea",{"type":36,"coordinates":37},"Point",[38,39],126.9784,37.566,{"lat":39,"lon":38},{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Jeong-Yeol Park, MD, PhD","professor","100622352","prospective-cohort-study-of-minimal-residual-diseasemrd-testing-for-early-recurrence-detection-in-endometrial-and-cervical-cancer-100622352",false,"NCT07382505","Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer","Prospective Cohort to Evaluate the Prognostic and Early-Recurrence Detection Performance of Blood-based Minimal Residual Disease (MRD) Testing in Endometrial and Cervical Cancer","Inclusion Criteria:\n\n* Histologically confirmed endometrial cancer or cervical cancer.\n* Scheduled for or completed standard treatment (Surgery, Adjuvant therapy, or CCRT).\n* Provision of written informed consent for study participation and biospecimen collection\n\nExclusion Criteria:\n\n* Synchronous other malignancies (cancer requiring treatment within the last 5 years).\n* Persistent infection or bleeding tendency that makes repeated blood collection unsafe.\n* Inability to follow-up or communicate (e.g., due to geographic or cognitive reasons).\n* Any condition that the principal investigator deems inappropriate for the study.","FEMALE",{"count":54,"type":55},600,"ESTIMATED","2 Years","OBSERVATIONAL","This study aims to evaluate the clinical performance of blood-based Minimal Residual Disease (MRD) testing using circulating tumor DNA (ctDNA) in patients with endometrial and cervical cancer. The researchers will investigate whether MRD detection can identify cancer recurrence earlier than current standard imaging or clinical methods (providing a \"lead time\"). Participants will undergo blood collection at specific time points, including at diagnosis, after surgery, and during regular follow-up visits. The study will also assess the correlation between MRD status and survival outcomes, such as Relapse-Free Survival (RFS) and Overall Survival (OS). The goal is to establish a foundation for personalized treatment strategies based on molecular monitoring.",[60,61],"Uterine Neoplasms","Cervical Cancer",[63,61,64,65,66,67],"Endometrial Cancer","Minimal Residual Disease","MRD","Circulating Tumor DNA","Liquid Biopsy","NOT_YET_RECRUITING","2026-01-27",{"date":71,"type":72},"2026-02-02","ACTUAL",{"date":74,"type":55},"2026-02-15",{"date":76,"type":55},"2027-12-31",{"name":5,"class":6},1]